Key takeaways
- Stage 4 pancreatic cancer means the cancer has spread from the pancreas to other parts of the body, such as the liver or lungs [1].
- It can't normally be cured, but treatment may help people live longer and relieve symptoms [1].
- In England, about 1 in 10 people with stage 4 disease were alive a year after diagnosis, and only around a quarter had treatment aimed at the cancer [2]. These figures describe groups, not individuals.
- A small number of people live for two years or longer with stage 4 disease. They are the exception, and nobody can promise that outcome [2] [3].
- Treatment keeps changing. The European Society for Medical Oncology (ESMO) now recommends testing the tumour at diagnosis, because a genetic change can open up extra options [4].
- Palliative care can start early in the illness and run alongside chemotherapy [5]. It isn't giving up.
A stage 4 pancreatic cancer diagnosis is one of the hardest things a person and their family can hear. You may be reading this because you want straight answers, not reassurance that skips over the truth. That is what this guide tries to give you.
We'll cover what stage 4 means, how symptoms tend to change, what the survival figures say and what they don't, which treatments exist today, and how to plan ahead with the people you love. No guide can tell you what will happen in your case; only your own care team can.
If you're a caregiver, you can also talk with others in a similar position in our online community for cancer support.
What Stage 4 Pancreatic Cancer Means
Doctors use four number stages for pancreatic cancer [1]. Stage 4 means the cancer has spread from the pancreas to other parts of the body, and doctors may also call it advanced or metastatic [1]. Even after it has spread, it is still pancreatic cancer, because that is where it started.
Locally advanced cancer is a different category. ESMO sorts pancreatic tumours into four groups (resectable, borderline resectable, locally advanced and advanced/metastatic) and takes into account how much a tumour is in contact with the blood vessels around the pancreas [6].
Pancreatic cancer may not cause any symptoms, or the symptoms may be hard to spot [7]. Many people are diagnosed late. In the 2025 report of the National Pancreatic Cancer Audit, which covers England and Wales, almost two-thirds of people already had stage 4 disease at diagnosis: 62% in England (2021 to 2022) and 65% in Wales (2022 to 2023) [2].
How Doctors Determine the Stage
Doctors can also stage pancreatic cancer with the TNM system, which stands for Tumour, Node, Metastases [1]. In stage 4 the original tumour can be any size and there may or may not be cancer cells in nearby lymph nodes, which TNM staging writes as "Any T, Any N, M1" [1].
CT of the chest, abdomen and pelvis is the main scan, and MRI can show liver metastases that CT misses [6]. A biopsy confirms the diagnosis when, for example, chemotherapy is about to start [6].
Where Pancreatic Cancer Spreads
When doctors look for spread, they check the liver, the lymph nodes, the peritoneum (the lining of the abdomen) and the lungs [6]. Where the cancer has spread affects which treatments your team suggests [1].
Common Symptoms of Stage 4 Pancreatic Cancer
Symptoms differ from person to person. The NHS lists yellow skin and eyes (jaundice), loss of appetite, losing weight without trying to, tiredness, pain at the top of the tummy and in the back, feeling or being sick, diarrhoea or constipation, and indigestion-type symptoms such as bloating [7]. New or worsening diabetes can also be a sign [6]. Several of these problems can be treated, so tell your team about any new or worsening symptom instead of waiting for your next appointment.
What Your Symptoms May Mean
This table can help you prepare questions for your team. It isn't a way to diagnose yourself.
| What you notice | What it may mean | Who to tell |
|---|---|---|
| Yellow skin or eyes, itchy skin, darker urine, paler stools [7] | Jaundice is a common presenting symptom of tumours in the head of the pancreas [6], and a stent in the bile duct can clear a blockage and prevent it [1] | Your care team promptly |
| Pain at the top of the tummy or in the back [7] | Abdominal pain is a common symptom of pancreatic cancer, and effective pain control is a major priority for many people with advanced disease [6] | Your care team or a pain specialist |
| Weight loss, loss of appetite, bloating, changes in your stools [7] | Too few digestive enzymes can cause weight loss, abdominal discomfort and greasy stools [6] | Your care team or a dietitian |
| New or worsening diabetes | A recognised sign of pancreatic cancer [6] | Your care team |
A new cough, breathlessness or a swollen tummy also deserve a call to your team, since many things can cause them.
Stage 4 Pancreatic Cancer Timeline: What to Expect
No one can give you a fixed timeline, but your team can describe the usual sequence: tests to confirm and stage the cancer, then chemotherapy if you're well enough, with a check on how it is working about every 8 to 12 weeks, based on how you are doing, a CA 19-9 blood test and scans [1] [6]. If the first treatment stops working, ESMO sets out second-line options [8].
How long each phase lasts varies a great deal. In the NAPOLI-3 trial of people starting first-line chemotherapy, the cancer took a median of 7.4 months to progress with NALIRIFOX and 5.6 months with gemcitabine plus nab-paclitaxel [8]. For people whose performance status is very poor (ECOG 3 to 4, a scale doctors use to describe how well you can manage daily activities), ESMO says symptom-directed care should be considered, because the risks of any chemotherapy are likely to outweigh the benefit [6].
Living with treatment and being close to the end of life are different situations, and your team can help you understand which one you're in. If treatment stops controlling the cancer, ask your team how care would change and how they would keep you comfortable. What stopping chemotherapy can mean is covered in our article on When the Oncologist Says No More Chemo: What It Means and What Comes Next. If you're thinking about care at home, you can read more in our guide on Hospice Care at Home: What to Expect in the Final Months.
Stage 4 Pancreatic Cancer Survival Rate and Life Expectancy
There's no gentle way to present these numbers, so we'll be direct. In the 2025 audit, 72% of people in England diagnosed with stage 4 disease in 2021 and 2022 were alive 30 days after diagnosis, 37% after 90 days and 10% after one year. The two-year figure, 3%, is for people diagnosed in 2020 and 2021. In Wales, the one-year figure was also 10% [2].
Those figures cover everyone in the audit with a stage 4 diagnosis, and only 27% of them in England received disease-targeted treatment, meaning treatment aimed at the cancer itself. Treatment rates differed sharply by performance status: in England, 49% of fully active people with metastatic disease were treated, compared with 3% of those with a performance status of 3 or 4 [2].
Trial results describe the people who took part. FOLFIRINOX, for example, was shown to be more effective than gemcitabine alone in people with an ECOG performance status of 0 to 1, meaning good general condition [6]. In that trial, median survival with gemcitabine was 6.8 months, and FOLFIRINOX added 4.3 months [8]. More recently, in NAPOLI-3 (770 people starting first-line chemotherapy), median survival was 11.1 months with NALIRIFOX and 9.2 months with gemcitabine plus nab-paclitaxel [8]. "Median" means half the people lived longer than that time and half didn't.
Understanding What the Statistics Actually Mean
Survival figures describe groups, not individuals, and they look backwards. The audit figures above come from people diagnosed before ESMO's 2025 and 2026 updates added new options [2] [4] [8], so they can't reflect those newer options.
Your own outlook depends on factors your team can assess. ESMO lists a poorer general condition (ECOG 2 or above), age over 65, low albumin (a blood protein), liver metastases, more metastatic sites and a high CA 19-9 level (a blood marker) as factors negatively associated with survival [6]. None of these is a verdict. They help explain why two people with the same stage can have very different experiences.
Remember: these are group figures, not your timeline. No number can tell you how your own illness will unfold. Use these figures to ask better questions, not to predict your future.
The Longest Someone Has Lived with Stage 4 Pancreatic Cancer
Many people want to know the longest anyone has lived with stage 4 pancreatic cancer, and the question deserves an honest answer. In England, 3% of people with stage 4 disease were alive two years after diagnosis [2]. A case report from the United States, published in 2024, goes further: it describes a woman with pancreatic and liver lesions who had chemotherapy for six years and had no evidence of disease six months after stopping. Its authors call it a rare case [3]. We share it for completeness, not as a forecast.
No one can tell you in advance whether you will be one of those exceptions. What is known is that some tumours carry genetic changes that make particular treatments work better. About 5% to 7% of patients of European descent, for example, carry an inherited BRCA variant, and their tumours are more susceptible to platinum chemotherapy and to PARP inhibitors (a type of targeted drug) such as olaparib [6]. In the POLO trial, olaparib given as maintenance after platinum chemotherapy delayed progression in people with an inherited BRCA variant (a median of 7.4 versus 3.8 months with placebo), although overall survival did not differ [6].
That is why one of the most useful questions you can ask is whether your tumour has been tested. ESMO now recommends molecular profiling at diagnosis for everyone with unresectable pancreatic cancer [4]. Testing can't promise a long survival, but it shows whether a targeted option is open to you.
Current Treatment Options for Stage 4 Pancreatic Cancer
Surgery is the only treatment that can potentially cure pancreatic cancer [6], but in stage 4 disease treatment won't cure the cancer [1]. You may see the word "unresectable", meaning cancer that surgery can't remove, in your notes. It doesn't mean "untreatable": the guideline from the National Institute for Health and Care Excellence (NICE) covers metastatic disease under its heading for unresectable pancreatic cancer [9]. Chemotherapy is the main treatment, and which regimen you're offered depends on how well you are [1].
Chemotherapy
For people in good general condition (ECOG performance status 0 to 1, no major other health problems and a bilirubin level below 1.5 times the upper limit of normal), ESMO recommends two regimens as first-line chemotherapy: FOLFIRINOX, which combines four drugs, or NALIRIFOX, which is similar but uses a liposomal form of irinotecan. Gemcitabine with nab-paclitaxel can also be used [8]. NICE's 2018 guideline says to offer FOLFIRINOX to people with metastatic pancreatic cancer and a performance status of 0 to 1, and to consider a gemcitabine combination for people who aren't well enough for it [9].
Retrospective real-world data suggest FOLFIRINOX is more active but also more toxic than gemcitabine with nab-paclitaxel, although ESMO noted there were no prospective randomised data comparing the two directly [6]. Side effects are a real part of treatment: in NAPOLI-3, serious (grade 3 or higher) adverse events occurred in 87% of people on NALIRIFOX and 86% on gemcitabine with nab-paclitaxel [8]. Tell your team early about any side effect, so they can help.
Testing Your Tumour, Targeted Drugs and Immunotherapy
Inherited BRCA changes matter for the reasons above, and a few other changes matter too. About 0.8% of pancreatic cancers have a mismatch repair problem (called MSI-high or dMMR), and ESMO says the immunotherapy drug pembrolizumab can be proposed for them as second-line or later treatment, although the data come from a small non-randomised trial of 22 people and the European Medicines Agency (EMA) had not approved the drug for pancreatic cancer when the guideline was published [6]. NTRK gene fusions, found in more than 1% of cases, can be targeted with drugs such as larotrectinib or entrectinib [6].
In 2026, ESMO recommended daraxonrasib after chemotherapy has stopped working for people whose tumours carry a RAS G12 mutation and who are fit enough (ECOG 0 to 1) [4]. In the RASolute 302 trial of 500 people, median survival in the RAS G12-mutated group was 13.2 months with daraxonrasib versus 6.6 months with chemotherapy, in a first interim analysis with a median follow-up of 8.5 months [4]. When the guideline was published, the drug was approved by the US Food and Drug Administration (FDA) but not by the EMA [4], so ask your team whether it is available where you live.

Managing Symptoms and Side Effects
A stent (a small tube placed in the bile duct) can clear a blockage and prevent symptoms such as jaundice [1] [9]. Pancreatic enzyme replacement therapy can help manage weight loss, abdominal discomfort and greasy stools caused by too few digestive enzymes [6], and NICE advises offering pancreatin to people with unresectable pancreatic cancer [9]. ESMO strongly recommends effective pain control, with a pain specialist involved when needed [6]. If pain is uncontrolled or painkillers cause unacceptable side effects, NICE says a nerve block (coeliac plexus block) can be considered [9].
A starting point for conversations with your care team:
| ✓ Do | ✗ Don't |
|---|---|
| Ask whether your tumour has been tested for BRCA and other actionable changes | Assume that "unresectable" means there is nothing to try |
| Ask about clinical trials early, not only when other options run out | Wait until the end of the treatment list to raise them |
| Bring a written list of questions to every appointment | Treat survival statistics as a forecast for you personally |
| Ask for a palliative care referral from the start | Think palliative care means giving up |
| Consider a second opinion at a specialist centre | Feel you have to decide everything in one visit |
Clinical Trials: Why to Ask Early
Clinical trials test new treatments and new combinations of existing ones, and they can be more than a last resort. Both NALIRIFOX and daraxonrasib reached the guidelines through phase III trials [4] [8]. For third-line treatment, ESMO says no standard regimen can be recommended and that, for people with a good performance status, joining a clinical trial is the first option when one is available [6].
Raise trials early, at diagnosis and at every decision point, and ask which ones you could join. A second opinion at a specialist centre can also be worth asking for, including whether that centre runs trials your local hospital doesn't.
Why Early Palliative Care Matters
The World Health Organization (WHO) defines palliative care as an approach that improves the quality of life of people facing life-threatening illness and of their families, and says it applies early in the course of illness, alongside treatments meant to prolong life, such as chemotherapy [5]. WHO's European office also lists misconceptions, such as that it is only for the last weeks of life, among the barriers to receiving it [5]. Asking for it doesn't mean you have stopped treatment.
An Italian randomised trial in 207 people with metastatic or locally advanced inoperable pancreatic cancer compared two ways of starting palliative care alongside standard cancer care. About half were scheduled to see a palliative care team routinely (systematic early palliative care) and the rest saw the team on demand, meaning only if they, their family or their oncologist asked. After 12 weeks, quality of life was better in the systematic group, and overall survival did not differ [10]. So the benefit shown was in how people felt, not in how long they lived.
The national audit made a related point. Because almost two-thirds of people are diagnosed at stage 4, its authors say the diagnostic work-up for these patients should be reviewed so they get supportive care input early [2].
You can ask for a palliative care referral yourself. WHO's European office says palliative care should be available in hospitals, palliative care units, hospices and, through home care teams, in primary care [5]. Our guide on Palliative Care vs Hospice: The Real Difference (And Why It Matters Now, Not Later) explains how the two differ, and our guide on What Is Palliative Care at Home? A Complete Guide for Patients and Families covers support at home.

Talking to Your Family and Planning Ahead
Some of the hardest parts of a stage 4 diagnosis aren't medical. Talking honestly with a partner, your children or close friends can feel overwhelming, and there is no single right way to do it. You decide how much to share and with whom, and that can change over time. It often helps to say what matters most to you, such as who you want around you and how you want to spend your time.
Planning ahead is part of that. Advance care planning means working out your goals and preferences for future medical treatment and care, talking them through with your family and your care team, and recording them [11]. You might write down your wishes and name someone you trust to speak for you if you can't. Planning ahead is a way of keeping a say in your care.
If you're the relative rather than the person with the diagnosis, you may worry about saying the wrong thing. Showing up matters more than finding perfect words. For help with the first conversations, see our article about What to Say to Someone with Cancer (and What Not to Say). For the later stages, see our article about What to Say to Someone Who Is Dying of Cancer.
Frequently Asked Questions
Can stage 4 pancreatic cancer be cured?
How long can you live with stage 4 pancreatic cancer?
It varies widely. In England, 37% of people with stage 4 disease were alive after 90 days and 10% after one year [2]. In the NAPOLI-3 trial of people starting first-line chemotherapy, median survival was 9.2 to 11.1 months, depending on the regimen [8]. Neither figure predicts what will happen to you. Your oncologist can give you an estimate based on your own situation.
Is stage 4 pancreatic cancer always terminal?
It usually is, in the sense that it can't normally be cured [1], and in England about 9 in 10 people with stage 4 disease were no longer alive a year after diagnosis [2]. But "terminal" doesn't tell you how much time you have, and it doesn't mean you're close to the end today. Palliative care is available at any stage after a diagnosis of advanced cancer [1].
What is the longest someone has lived with stage 4 pancreatic cancer?
A published case report describes a woman who lived for six years with metastatic pancreatic cancer and had no evidence of disease after stopping chemotherapy. Its authors call hers a rare case [3]. Her story isn't typical, and nobody can promise a similar outcome.
Does a stage 4 diagnosis mean I should start hospice?
Not necessarily. Palliative care can start early in the illness and run alongside chemotherapy, and hospices are only one of the places where it should be available [5]. Ask your team what each would add for you.
Facing the Diagnosis with Clarity and Support
Stage 4 pancreatic cancer is serious, and the numbers are hard to read. We can't soften that. But treatment exists, support is available, and no average describes you.
Three questions are worth asking at your next appointment. Has my tumour been tested, and what could the results change? Which clinical trials could I join? Can I see a palliative care team now? Bring your questions in writing, and lean on the people around you.
You and your family don't have to go through this alone. When you're ready, you can talk with others in our online community for cancer support.
References
[1] Cancer Research UK. (2026, August 20). Stage 4 pancreatic cancer. Retrieved November 17, 2026, from https://www.cancerresearchuk.org/about-cancer/pancreatic-cancer/stages-types-grades/stage-4
[2] National Pancreatic Cancer Audit. (2025). State of the Nation report 2025 (Version 2). National Cancer Audit Collaborating Centre, Royal College of Surgeons of England. https://www.hqip.org.uk/wp-content/uploads/2025/09/REF634NATCAN-NPaCA_SoN_FINAL-v2.0.pdf
[3] Burke, C. E., Eng, N. L., Yee, N. S., & Peng, J. S. (2024). Complete response to chemotherapy in a 6-year survivor of metastatic pancreatic cancer. BMJ Case Reports, 17(7), Article e261008. https://doi.org/10.1136/bcr-2024-261008
[4] Conroy, T., & Ducreux, M. (2026). ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer. Annals of Oncology, 37(11), 1463-1466. https://doi.org/10.1016/j.annonc.2026.08.003
[5] World Health Organization Regional Office for Europe. (2023, June 1). Palliative care [Fact sheet]. https://www.who.int/europe/news-room/fact-sheets/item/palliative-care
[6] Conroy, T., Pfeiffer, P., Vilgrain, V., Lamarca, A., Seufferlein, T., O'Reilly, E. M., Hackert, T., Golan, T., Prager, G., Haustermans, K., Vogel, A., & Ducreux, M. (2023). Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 34(11), 987-1002. https://doi.org/10.1016/j.annonc.2023.08.009
[7] NHS. (2023, June 9). Symptoms of pancreatic cancer. Retrieved November 17, 2026, from https://www.nhs.uk/conditions/pancreatic-cancer/symptoms/
[8] Conroy, T., & Ducreux, M. (2025). ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer. ESMO Open, 10(4), Article 104528. https://doi.org/10.1016/j.esmoop.2025.104528
[9] National Institute for Health and Care Excellence. (2018, February 7). Pancreatic cancer in adults: Diagnosis and management (NICE guideline NG85). Retrieved November 17, 2026, from https://www.nice.org.uk/guidance/NG85/chapter/Recommendations
[10] Maltoni, M., Scarpi, E., Dall'Agata, M., Zagonel, V., Bertè, R., Ferrari, D., Broglia, C. M., Bortolussi, R., Trentin, L., Valgiusti, M., Pini, S., Farolfi, A., Casadei Gardini, A., Nanni, O., Amadori, D., Frassineti, G. L., Sansoni, E., Ragazzini, A., Ruscelli, S., . . . Montanari, L. (2016). Systematic versus on-demand early palliative care: Results from a multicentre, randomised clinical trial. European Journal of Cancer, 65, 61-68. https://doi.org/10.1016/j.ejca.2016.06.007
[11] Rietjens, J. A. C., Sudore, R. L., Connolly, M., van Delden, J. J., Drickamer, M. A., Droger, M., van der Heide, A., Heyland, D. K., Houttekier, D., Janssen, D. J. A., Orsi, L., Payne, S., Seymour, J., Jox, R. J., Korfage, I. J., & European Association for Palliative Care. (2017). Definition and recommendations for advance care planning: An international consensus supported by the European Association for Palliative Care. The Lancet Oncology, 18(9), e543-e551. https://doi.org/10.1016/S1470-2045(17)30582-X
